IFM Investors Pty Ltd Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

IFM Investors Pty Ltd acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,742 shares of the biotechnology company's stock, valued at approximately $2,238,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. raised its stake in United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company's stock worth $114,000 after acquiring an additional 46 shares in the last quarter. Formidable Asset Management LLC raised its stake in United Therapeutics by 1.5% during the third quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company's stock worth $821,000 after acquiring an additional 53 shares in the last quarter. Alaska Permanent Fund Corp raised its stake in United Therapeutics by 1.7% during the third quarter. Alaska Permanent Fund Corp now owns 3,330 shares of the biotechnology company's stock worth $752,000 after acquiring an additional 57 shares in the last quarter. MBM Wealth Consultants LLC raised its stake in United Therapeutics by 2.7% during the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company's stock worth $515,000 after acquiring an additional 59 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in United Therapeutics by 1.6% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company's stock worth $856,000 after acquiring an additional 61 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,869,150.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other United Therapeutics news, Director Christopher Patusky sold 1,680 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $224.00, for a total transaction of $376,320.00. Following the transaction, the director now directly owns 4 shares in the company, valued at approximately $896. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $215.01, for a total value of $1,290,060.00. Following the transaction, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The disclosure for this sale can be found here. Insiders have sold 136,990 shares of company stock worth $32,239,641 over the last ninety days. Insiders own 12.50% of the company's stock.

United Therapeutics Trading Down 0.9 %

UTHR stock traded down $2.10 during trading on Friday, hitting $233.85. The company had a trading volume of 369,691 shares, compared to its average volume of 473,041. The business has a 50-day moving average of $233.74 and a 200-day moving average of $228.80. United Therapeutics Co. has a one year low of $204.44 and a one year high of $261.54. The stock has a market cap of $11.00 billion, a PE ratio of 11.79 and a beta of 0.52. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating the consensus estimate of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business had revenue of $614.70 million for the quarter, compared to analysts' expectations of $575.01 million. During the same period in the prior year, the business posted $2.67 earnings per share. The firm's revenue was up 25.1% on a year-over-year basis. Research analysts predict that United Therapeutics Co. will post 23.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on UTHR shares. Wells Fargo & Company boosted their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an "overweight" rating in a research note on Thursday, March 7th. SVB Leerink began coverage on United Therapeutics in a research note on Monday, February 5th. They issued an "outperform" rating and a $330.00 price objective for the company. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, April 11th. Leerink Partnrs reaffirmed an "outperform" rating on shares of United Therapeutics in a research note on Monday, February 5th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $294.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.